Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.35 |
| ▸ | MTOR | P42345 | 5/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5856825 | 1.00 | BACE1 (0.36) | BACE1NAMPTPIK3CAMTORPIK3CG | |
| SCHEMBL3933124 | 0.90 | PIK3CA (0.35) | NAMPTPIK3CAMTORPIK3CGPIK3CB | |
| SCHEMBL3933118 | 0.90 | PIK3CA (0.35) | NAMPTPIK3CAMTORPIK3CGPIK3CB | |
| SCHEMBL3931660 | 0.90 | PIK3CA (0.35) | PIK3CAMTORPIK3CGROCK2 | |
| SCHEMBL5857325 | 0.90 | PIK3CA (0.35) | PIK3CAMTORPIK3CGROCK2 | |
| SCHEMBL5858209 | 0.89 | CASP3 (0.43) | NAMPTRAB9A | |
| SCHEMBL3935882 | 0.89 | CASP3 (0.43) | NAMPTRAB9A | |
| SCHEMBL5858467 | 0.89 | BACE1 (0.35) | BACE1TGM2FLT3 | |
| SCHEMBL3934951 | 0.89 | BACE1 (0.35) | BACE1TGM2FLT3 | |
| SCHEMBL5856908 | 0.87 | BACE1 (0.35) | BACE1TGM2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551830-B1 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-7148249-B2 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-12-12 | — | — | US | disclosed |
| EP-1551830-A2 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-13 | — | — | EP | disclosed |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
| WO-2004026829-A2 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | CDK1, CDK2, CDK3 | BACE1 1424/4885NAMPT 1870/4885PIK3CA 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.